Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients

Journal of Psychopharmacology

Volumn 24, Issue 7, 2010, Pages 987-994

  Yasui Furukori, N ^a   Saito, M ^a   Nakagami, T ^a   Furukori, H ^a   Suzuki, A ^b   Kondo, T ^c   Kaneko, S ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c University of the Ryukyus   (Japan)

Author keywords

Active moiety; Clinical response; Drug concentration; Risperidone; Schizophrenia

Indexed keywords

PALIPERIDONE; RISPERIDONE;

ACCOMMODATION PARALYSIS; ADOLESCENT; ADULT; AGED; AKATHISIA; ARTICLE; ASTHENIA; BRIEF PSYCHIATRIC RATING SCALE; CONCENTRATION LOSS; CONSTIPATION; DEPRESSION; DISEASE EXACERBATION; DIZZINESS; DRUG BLOOD LEVEL; DYSTONIA; FEMALE; HEART PALPITATION; HUMAN; HYPERKINESIA; HYPOKINESIA; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MICTURITION DISORDER; ORTHOSTATIC DIZZINESS; PRIORITY JOURNAL; RIGIDITY; SALIVATION; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TENSION; TREMOR;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; ANXIETY; COGNITION; DATA INTERPRETATION, STATISTICAL; DEPRESSION; FEMALE; HOSPITALIZATION; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953802438     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109104849     Document Type: Article

References (31)

1. Ambudkar, SV, Dey, S., Hrycyna, CA, Ramachandra, M., Pastan, I., Gottesman, MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398.
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, fourth ed. Washington, DC: American Psychiatric Association (Revised).
3. Aravagiri, M., Marder, SR (2002) Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology 159: 424-431.
4. Bech, P., Kastrup, M., Rafaelsen, OJ (1986) Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand 73 (Suppl. 326). 1S - S37.
5. Benet, LZ, Izumi, T., Zhang, Y., Silverman, JA, Wacher, VJ (1999) Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. Control Release 62: 25-31.
6. Chouinard, G., Jones, B., Remington, G., Bloom, D., Addington, D., MacEwan, GW, et al. (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 25-40.
7. Claus, A., Bollen, J., De Cuyper, H., Eneman, M., Malfroid, M., Peuskens, J., et al. (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicenter double-blind comparative study. Acta Psychiatr Scand 85: 295-305.
8. Cohen, H. (2005) Anxiolytic effect and memory improvement in rats by antisense oligodeoxynucleotide to 5-hydroxytryptamine-2A precursor protein. Depress Anxiety 22: 84-93.
9. Doran, A., Obach, RS, Smith, BJ, Hosea, NA, Becker, S., Callegari, E., et al. (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33: 165-174.
10. Goldstein, M., Deutch, AY (1992) Dopaminergic mechanisms in the pathogenesis of schizophrenia. FASEB J 6: 2413-2421.
11. Gunes, A., Spina, E., Dahl, ML, Scordo, MG (2008) ABCB1 Polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit 30: 628-633.
12. Huang, ML, Van Peer, A., Woestenborghs, R., De Coster, R., Heykants, J., Jansen, AA, et al. (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54: 257-268.
13. Janssen, PA, Niemegeers, CJ, Awouters, F., Schellekens, KH, Megens, AA, Meert, TF (1988) Pharmacology of risperidone (R 64 766). a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244: 685-693.
14. Kakihara, S., Yoshimura, R., Shinkai, K., Matsumoto, C., Goto, M., Kaji, K., et al. (2005) Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 20: 71-78.
15. Kondo, T., Mihara, K., Yasui, N., Nagashima, U., Ono, S., Kaneko, S., et al. (2000) Therapeutic spectrum of nemonapride and its relationship with plasma concentrations of the drug and prolactin. J Clin Psychopharmacol 20: 404-409.
16. Leysen, JE, Gommeren, W., Eens, A. de Chaffoy de Courcelles, D., Stoof, JC, Janssen, PA (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247: 661-670.
17. Lindenmayer, JP, Bernstein-Hyman, R., Grochowski, S., Bark, N. (1995) Psychopathology of schizophrenia: Initial validation of A 5-Factor model. Psychopathology 28: 22-31.
18. Lingjaerde, O., Ahlfors, UG, Bech, P., Dencker, SJ, Elgen, K. (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 334 (Suppl.). 1-100.
19. Mannens, G., Huang, ML, Meuldermans, W., Hendrickx, J., Woestenborghs, R., Heykants, J. (1993) Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 21: 1134-1141.
20. Nakagami, T., Yasui-Furukori, N., Saito, M., Tateishi, T., Kaneko, S. (2005) Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther 78: 43-51.
21. Olesen, OV, Licht, RW, Thomsen, E., Bruun, T., Viftrup, JE, Linnet, K. (1998) Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 20: 380-384.
22. Riedel, M., Schwarz, MJ, Strassnig, M., Spellmann, I., Müller-Arends, A., Weber, K., et al. (2005) Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 255: 261-268.
23. Schotte, A., Janssen, PF, Gommeren, W., Luyten, WH, Van Gompel, P., Lesage, AS, et al. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124: 57-73.
24. Scordo, MG, Spina, E., Facciola, G., Avenoso, A., Johansson, I., Dahl, ML (1999) Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology 147: 300-305.
25. Snoeck, E., Van Peer, A., Sack, M., Horton, M., Mannens, G., Woestenborghs, R., et al. (1995) Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 122: 223-229.
26. Spina, E., Avenoso, A., Facciola, G., Salemi, M., Scordo, MG, Ancione, M., et al. (2001) Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology 153: 238-243.
27. van Beijsterveldt, LE, Geerts, RJ, Leysen, JE, Megens, AA, Van den Eynde, HM, Meuldermans, WE, et al. (1994) The regional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the rat. Psychopharmacology 114: 53-62.
28. Wang, JS, Ruan, Y., Taylor, RM, Donovan, JL, Markowitz, JS, DeVane, CL (2004) The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 7: 415-419.
29. Yasui-Furukori, N., Kondo, T., Ishida, M., Furukori, H., Suzuki, A., Kaneko, S., et al. (2002) Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms. Prog Neuropsychopharmacol Biol Psychiatry 26: 53-57.
30. Yasui-Furukori, N., Mihara, K., Takahata, T., Suzuki, A., Nakagami, T., De Vries, R., et al. (2004) Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol 57: 569-575.
31. Yoshimura, R., Ueda, N., Nakamura, J. (2001) Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study. Neuropsychobiology 44: 129-133.